P. Rosen

发表

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer

M. Borad, D. Ryan, S. Kroll, 2012 .

Hepatoblastoma in infant sisters

J. Fraumeni, S. Shapiro, J. Fraumeni, 1969, Cancer.

A phase II trial of irinotecan in hormone-refractory prostate cancer

D. Prager, P. Rosen, D. Reese, 1998, Investigational New Drugs.

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma

J. Hecht, D. Prager, L. Rosen, 2002, Cancer.

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

John W. Adams, M. Berger, M. Edelman, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

Suzanne F. Jones, E. Sausville, K. Papadopoulos, 2013, Cancer Chemotherapy and Pharmacology.

Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.

A. Gomes, J. Sayre, R. Busuttil, 2009, AJR. American journal of roentgenology.

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

M. Territo, C. Emmanouilides, P. Rosen, 2003, Hematological oncology.

Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab')2 monoclonal antibody

A. Epstein, C. Taylor, P. Rosen, 1991 .

Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma.

W. Grody, L. Bosserman, C. Emmanouilides, 2000, Clinical lymphoma.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.

W. Grody, M. Territo, C. Emmanouilides, 2002, Clinical lymphoma.

Convoluted lymphocytic lymphoma in adults: a clinicopathologic entity.

J. Parker, R. Lukes, P. Rosen, 1978, Annals of internal medicine.

Oncogenic osteomalacia associated with prostate cancer.

P. Rosen, D. Reese, 1997, The Journal of urology.

Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.

S. Groshen, C. Spears, C. Leichman, 1993, Journal of the National Cancer Institute.

Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial

M. Territo, C. Emmanouilides, P. Rosen, 1998, Hematological oncology.

Lymphocyte-depletion Hodgkin's disease.

R. Lukes, R. Neiman, P. Rosen, 1973, British medical journal.

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

M. Cazzola, T. Barbui, H. Kantarjian, 2009 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria

R. Paquette, P. Rosen, L. Kunkel, 1997, British journal of haematology.

Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity.

R. Lukes, R. Neiman, P. Rosen, 1973, The New England journal of medicine.

Biological Modification of protracted infusion of 5-fluorouracil with weekly leucovorin

F. Muggia, C. Leichman, L. Leichman, 1990, Cancer Chemotherapy and Pharmacology.

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.

F. Appelbaum, C. Rankin, D. Head, 2000, Leukemia research.

Autoimmune Myelofibrosis: A Steroid‐Responsive Cause of Bone Marrow Fibrosis Associated with Systemic Lupus Erythematosus

R. Paquette, P. Rosen, A. Meshkinpour, 1994, Medicine.

Bleeding problems in the cancer patient.

P. Rosen, P. Rosen, 1992, Hematology/oncology clinics of North America.

Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency.

E. Beutler, P. Rosen, W. McGehee, 1971, Annals of internal medicine.

Severe transient pancytopenia associated with procainamide ingestion.

A. Bluming, P. Rosen, A. Thiessen, 1976, JAMA.

Tamoxifen flare in advanced breast cancer.

P. Rosen, J. Lechner, D. Plotkin, 1978, JAMA.

Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies

F. Muggia, R. Ko, P. Rosen, 2008, Cancer Chemotherapy and Pharmacology.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

M. Cazzola, T. Barbui, H. Kantarjian, 2013, Cancer.

Study of leukocyte kinetics in acute myelocytic leukemia utilizing chromium-51.

S. Perry, H. Eyre, D. Lilien, 1975, Medical and pediatric oncology.

Relative labeling of leukocytes, erythrocytes and platelets in human blood by 51-chromium.

S. Perry, H. Eyre, P. Rosen, 1970, Blood.

A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung

R. Herbst, Z. Shun, V. Miller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

P. Albers, H. Scher, G. Heller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.

A. Belldegrun, E. Landaw, J. Dekernion, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)

R. Herbst, V. Miller, L. Hart, 2007 .

A phase II trial of CI-921 in advanced malignancies

N. Robert, J. Doroshow, L. Panasci, 1992, Investigational New Drugs.

A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies

T. Morgan, P. Rosen, H. Ozer, 1991 .

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

T. Spektor, J. Berenson, P. Rosen, 2018, British journal of haematology.

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

J. Berenson, P. Rosen, A. Bessudo, 2012 .

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

S. Groshen, J. Friedberg, K. Venkatakrishnan, 2018, Clinical Cancer Research.

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors.

S. Sahasrabudhe, G. Weiss, D. V. Hoff, 2010 .

Acute lymphocytic leukemia manifesting as splenic rupture.

P. Rosen, W. Sheehan, C. Johnson, 1979, American journal of clinical pathology.

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

Dorothy J. Park, C. Sweeney, K. Oliner, 2010, Clinical Cancer Research.

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2009 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.

M. Territo, G. Schiller, C. Emmanouilides, 2004, Clinical lymphoma.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients

R. Elashoff, R. Figlin, A. Belldegrun, 1996, Cancer.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

J. Crowley, M. Hidalgo, N. Raghunand, 2014, Cancer Chemotherapy and Pharmacology.

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

P. Rosen, I. Tabbara, P. Ács, 2013, Annals of Hematology.

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

S. Trudel, O. O’Connor, A. Goy, 2012, Clinical Cancer Research.

A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

D. Schenkein, P. Rosen, D. Fernando, 2005 .

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

M. Borad, D. Ryan, S. Kroll, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies.

T. Morgan, P. Rosen, H. Ozer, 1991, Medical and pediatric oncology.

American studies on suramin therapy in hormone resistant prostate cancer.

A. Belldegrun, P. Rosen, 1995, Cancer surveys.

Proliferative capacity of leukemic cells in AKR leukemia.

S. Perry, F. Schabel, P. Rosen, 1970, Journal of the National Cancer Institute.

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Camidge, J. Spicer, A. Mita, 2010 .

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

R. Loberg, R. Kurzrock, F. Janku, 2015, Oncotarget.

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

M. Cazzola, T. Barbui, H. Kantarjian, 2010 .

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

M. Cazzola, T. Barbui, H. Kantarjian, 2012 .

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.

J. Hecht, L. Rosen, R. Amado, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity

W. Read, D. Park, R. Tibes, 2008 .

Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.

E. Sausville, K. Papadopoulos, A. Patnaik, 2010 .

Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent.

R. Korn, N. Raghunand, W. Read, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

J. Friedberg, B. Holkova, A. Forero-Torres, 2013 .

Measuring the Ability of Primary-Care Physicians To Diagnose and Manage Patients with Hematologic Malignancies.

R. Wender, P. Rosen, Scott L. Kober, 2007 .

First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors.

R. Loberg, R. Kurzrock, F. Janku, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors

E. Rasmussen, D. Park, C. Sweeney, 2008 .

Treatment of advanced lymphomas with bleomycin (NSC-125066).

T. Pajak, P. Rosen, J. Bateman, 1976, Oncology.

Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

A. Tolcher, K. Papadopoulos, S. Crippa, 2010 .